Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Industry Collaboration Targets Patient-Reported Outcomes Tools In Cancer

Executive Summary

Industry efforts to collaborate on drug development issues have moved into the arena of patient-reported outcomes, with a consortium forming to improve ways patients report cancer-related fatigue

You may also be interested in...



Antibiotic Trials For COPD May Hinge On Patient-Reported Outcomes, FDA Says

Outcomes that are clinically important to patients should be the focus of clinical trials for antibiotics to treat acute bacterial exacerbation of chronic bronchitis in patients with chronic obstructive pulmonary disease, FDA recommends in a 1draft guidance released Aug. 21

Antibiotic Trials For COPD May Hinge On Patient-Reported Outcomes, FDA Says

Outcomes that are clinically important to patients should be the focus of clinical trials for antibiotics to treat acute bacterial exacerbation of chronic bronchitis in patients with chronic obstructive pulmonary disease, FDA recommends in a 1draft guidance released Aug. 21

Nephrotoxicity Biomarker Prepares For Clinic After FDA Blesses Animal Test

The firms that obtained FDA/EMEA qualification of seven nephrotoxicity biomarkers for preclinical drug testing are midway through development of a protocol to test their efficacy in a clinical trial

Related Content

UsernamePublicRestriction

Register

PS049889

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel